The development process of antiviral therapies typically requires years before the therapies can be made widely available27 because there are a number of regulatory steps required to establish the safety and efficacy of vaccines and drugs.28 Moreover, the highly specific viral targets might change as SARS-CoV-2 continues to mutate, resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31).